Medical versus surgical androgen suppression therapy for prostate cancer: A 10-year longitudinal cost study

Purpose: We provide a relative cost comparison of medical versus surgical a ndrogen suppressive therapy for prostate cancer. Materials and Methods: Comparison is based on a cohort of 96 patients who b egan androgen suppressive therapy for prostate cancer between 1988 and 1990 . Patients were followed until death or the end point of study in June 2000 at which time 15% were alive. Current Medicare orchiectomy reimbursements were compared to 1999 wholesale drug costs. Results: For an individual patient the cost of luteinizing hormone releasin g hormone (LH-RH) agonist treatment surpassed the cost of surgery at less t han 4.2 to 5.3 months, and for combined androgen blockade (LH-RH agonists a nd nonsteroidal antiandrogens) at less than 2.7 to 3.4 months. For 5 (5.2%) patients on combined androgen blockade and 6 (6.3%) on LH-RH agonists alon e, medical therapy would have had a cost advantage over bilateral orchiecto my. For the androgen suppression cohort the cost of LH-RH agonist treatment was 10.7 to 13.5 times and combined androgen blockade was 17.3 to 20.9 tim es the cost of bilateral orchiectomy. Urology resource use comparisons are provided. These findings significantly underestimate the cost advantage of surgery. A seventh of the patients were alive at study end point, and prost ate specific antigen induced stage shifting and changes in practice pattern s resulted in earlier and more frequent androgen suppressive treatment. Conclusions: Except for patients with short anticipated survivals current m edical androgen suppressive treatment options are more costly than bilatera l orchiectomy. There is a need for a cost comparable medical option to orch iectomy.